Cambridgeshire -- (MARKET WIRE) -- January 23, 2007 --
For Immediate Release 23 January 2007
BioProgress plc
Product Development Update
London, UK, 23 January 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the speciality pharma and healthcare company,
announces that it has successfully achieved indicative stability for its DBP117
Migraine treatment product using its propriety Soluleaves™ technology. It has
also developed the patented nicotine DBP121 thin strip product, which will
shortly be entering stability for the smoking cessation market. Both products
are designed to undergo rapid development and commercialisation.
Both proprietary developed products use established molecules and are the first
in a series of product developments incorporating potent pharmaceutical
products. The work undertaken so far by the dedicated team at BioProgress has
been able to generate the high level of manufacturing standards required to
register a potent drug in a melt-in-a-mouth film.
Both product developments represent novel forms of pharmaceuticals with rapid
and sustained release characteristics. The potential market for DBP117 is valued
at $3.3 billion (Datamonitor 2006). The nicotine replacement market was over
GBP88m in the UK alone in 2005. In both cases the products are global and possess
unique intellectual property enabling marketing on a worldwide basis.
Steve Martin, Chief Development Officer said:
"We are in discussions on these exciting and novel product forms of
pharmaceuticals with a number of potential licensing partners, including global
top10 pharmaceutical companies."
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich / Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL™ polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.
This information is provided by RNS
The company news service from the London Stock Exchange